Posted by Michael Wonder on 14 Jun 2020
Dementia drug choline alfoscerate to get limited insurance benefit
12 June 2020 - The government has allowed choline alfoscerate, a dementia drug, to continue to receive the national health insurance benefit only for the secondary symptoms caused by cerebrovascular defects. The announcement came after the government’s reassessment of the drug’s reimbursement.
It also allowed Bavencio (avelumab), a newly authorised drug for metastatic Merkel cell carcinoma, to be reimbursable.
The Health Insurance Review and Assessment Service said it held the sixth meeting of the Health Insurance Drug Reimbursement Committee and released the decision on the two medicines on Thursday.
